Department of Pediatric Dentistry, Hamidiye Faculty of Dental Medicine, University of Health Sciences, Istanbul, Turkey.
Department of Pediatric Dentistry, Hamidiye Faculty of Dental Medicine, University of Health Sciences, Istanbul, Turkey.
J Dent. 2024 Nov;150:105378. doi: 10.1016/j.jdent.2024.105378. Epub 2024 Oct 9.
The objective of this clinical trial was to evaluate and compare the clinical and radiographic successes of three bioactive endodontic cements (BEC) including novel portland cement-based material releasing fluoride, resin-modified silicate glass cement, and pure tricalcium silicate-based cement-in the treatment of primary molars diagnosed with reversible pulpitis via indirect pulp capping.
Eighty-six (86) participants with previously untreated first and second primary molars were included in this study. The teeth were randomly allocated into three groups: pure tricalcium silicate-based cement, resin-modified silicate glass cement, and novel portland cement-based material releasing fluoride. Cavities were capped with the assigned cement after caries excavation using standard protocols. The teeth that underwent treatment were restored using glass ionomer cement and composite resin. Clinical and radiographic evaluations were performed at 1, 6, and 12 months. The data were analyzed using Pearson chi-square, Kruskal-Wallis H and Z test (P = 0.05).
The success rate was 88 % (n = 25) in the pure tricalcium silicate-based cement group, 88.5 % (n = 26) in the resin-modified silicate glass cement group, and 100 % (n = 25) in the novel portland cement-based material releasing fluoride group. The differences at the 1st, 6th, and 12th month follow-up visits were not statistically significant among the groups (P > 0.05). No difference was found between the integrity of the resin composite restorations overlying pure tricalcium silicate-based cement, resin-modified silicate glass cement, and novel portland cement-based material releasing fluoride according to the USPHS criteria.
Novel portland cement-based material releasing fluoride can be considered an alternative for preserving the tooth, as it showed a high success rate in treating primary molars diagnosed with reversible pulpitis via indirect pulp capping.
Novel Portland cement-based material releasing fluoride could be beneficial in the treatment of primary molars diagnosed with reversible pulpitis via indirect pulp capping.
本临床试验的目的是评估和比较三种生物活性根管水泥（BEC）的临床和放射学效果，包括新型波特兰水泥基释放氟化物的材料、树脂改性硅酸盐水凝水泥和纯硅酸三钙基水泥，用于治疗经间接盖髓术诊断为可逆性牙髓炎的乳磨牙。
本研究纳入了 86 名未经治疗的第一和第二乳磨牙患者。这些牙齿被随机分配到三组：纯硅酸三钙基水泥组、树脂改性硅酸盐水凝水泥组和新型波特兰水泥基释放氟化物的材料组。采用标准方案进行龋蚀去除后，用指定的水泥进行窝洞封闭。用玻璃离子水门汀和复合树脂修复接受治疗的牙齿。在 1、6 和 12 个月时进行临床和放射学评估。使用 Pearson 卡方检验、Kruskal-Wallis H 和 Z 检验（P = 0.05）分析数据。
纯硅酸三钙基水泥组的成功率为 88%（n = 25），树脂改性硅酸盐水凝水泥组为 88.5%（n = 26），新型波特兰水泥基释放氟化物组为 100%（n = 25）。在第 1、6 和 12 个月的随访中，各组之间的成功率差异无统计学意义（P > 0.05）。根据 USPHS 标准，在纯硅酸三钙基水泥、树脂改性硅酸盐水凝水泥和新型波特兰水泥基释放氟化物上覆盖的树脂复合修复体的完整性没有差异。
新型波特兰水泥基释放氟化物可被视为保留牙齿的一种选择，因为它在经间接盖髓术诊断为可逆性牙髓炎的乳磨牙治疗中显示出较高的成功率。
新型波特兰水泥基释放氟化物可能有益于经间接盖髓术诊断为可逆性牙髓炎的乳磨牙治疗。
